SEC Filing | GE HealthCare

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rott Roland

(Last)

(First)

(Middle)

500 W. MONROE STREET

(Street)

CHICAGO

60661

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
GE HealthCare Technologies Inc. [ GEHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CEO, Ultrasound

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.01 per share	01/03/2023		A		245⁽¹⁾	A	⁽¹⁾	245	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$142.15	01/04/2023		A		643		⁽²⁾	09/05/2024	Common stock, par value $0.01 per share	643	⁽¹⁾	643	D
Employee Stock Option (right to buy)	$135.92	01/04/2023		A		735		⁽²⁾	09/11/2025	Common stock, par value $0.01 per share	735	⁽¹⁾	735	D
Employee Stock Option (right to buy)	$161.3	01/04/2023		A		552		⁽²⁾	09/30/2026	Common stock, par value $0.01 per share	552	⁽¹⁾	552	D
Employee Stock Option (right to buy)	$99.21	01/04/2023		A		919		⁽²⁾	11/17/2027	Common stock, par value $0.01 per share	919	⁽¹⁾	919	D
Employee Stock Option (right to buy)	$88.67	01/04/2023		A		13,773		⁽²⁾	01/29/2028	Common stock, par value $0.01 per share	13,773	⁽¹⁾	13,773	D
Employee Stock Option (right to buy)	$76.66	01/04/2023		A		1,639		⁽²⁾	03/19/2028	Common stock, par value $0.01 per share	1,639	⁽¹⁾	1,639	D
Employee Stock Option (right to buy)	$76.66	01/04/2023		A		2,296		⁽²⁾	03/19/2028	Common stock, par value $0.01 per share	2,296	⁽¹⁾	2,296	D
Employee Stock Option (right to buy)	$40.4	01/04/2023		A		13,275		⁽²⁾	12/21/2028	Common stock, par value $0.01 per share	13,275	⁽¹⁾	13,275	D
Employee Stock Option (right to buy)	$57.74	01/04/2023		A		3,727		⁽²⁾	03/19/2029	Common stock, par value $0.01 per share	3,727	⁽¹⁾	3,727	D
Employee Stock Option (right to buy)	$51.67	01/04/2023		A		1,614		⁽²⁾	04/11/2029	Common stock, par value $0.01 per share	1,614	⁽¹⁾	1,614	D
Employee Stock Option (right to buy)	$63.51	01/04/2023		A		7,214		⁽³⁾	03/02/2030	Common stock, par value $0.01 per share	7,214	⁽¹⁾	7,214	D
Employee Stock Option (right to buy)	$75.24	01/04/2023		A		8,536		⁽⁴⁾	04/01/2031	Common stock, par value $0.01 per share	8,536	⁽¹⁾	8,536	D
Restricted Stock Units	⁽⁵⁾	01/04/2023		A		1,081		⁽⁶⁾	⁽⁶⁾	Common stock, par value $0.01 per share	1,081	⁽¹⁾	1,081	D
Restricted Stock Units	⁽⁵⁾	01/04/2023		A		6,519		⁽⁷⁾	⁽⁷⁾	Common stock, par value $0.01 per share	6,519	⁽¹⁾	6,519	D
Restricted Stock Units	⁽⁵⁾	01/04/2023		A		3,713		⁽⁸⁾	⁽⁸⁾	Common stock, par value $0.01 per share	3,713	⁽¹⁾	3,713	D
Restricted Stock Units	⁽⁵⁾	01/04/2023		A		3,347		⁽⁹⁾	⁽⁹⁾	Common stock, par value $0.01 per share	3,347	⁽¹⁾	3,347	D
Restricted Stock Units	⁽⁵⁾	01/04/2023		A		5,828		⁽¹⁰⁾	⁽¹⁰⁾	Common stock, par value $0.01 per share	5,828	⁽¹⁾	5,828	D

Explanation of Responses:

1. The transactions reported herein are the result of the consummation on January 3, 2023 of the distribution of approximately 80.1% of the shares of common stock of GE HealthCare Technologies Inc. ("GE HealthCare") by General Electric Company ("GE") to holders of GE common stock on a pro rata basis (the "Spin-Off"). These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

2. Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 100% is fully exercisable immediately.

3. Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% is exercisable immediately and 50% will become exercisable on March 2, 2023.

4. Award of an employee stock option with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% will become exercisable on April 1, 2023 and 50% will become exercisable on April 1, 2024.

5. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare common stock.

6. Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 100% will vest on March 2, 2023.

7. Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% will vest on August 3, 2023 and 50% will vest on August 3, 2024.

8. Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% will vest on March 1, 2023 and 50% will vest on March 1, 2024.

9. Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% will vest on April 1, 2023 and 50% will vest on April 1, 2024.

10. Award of restricted stock units with respect to GE HealthCare common stock resulting from the conversion of certain equity incentive awards previously granted by GE as a result of the Spin-Off, of which 50% will vest on March 1, 2024 and 50% will vest on March 1, 2025.

Remarks:

	/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact	01/05/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.